Discovery of SARS-CoV-2 M ^pro peptide inhibitors from modelling substrate and ligand binding

Abstract

The main protease (M pro ) of SARS-CoV-2 is central to viral maturation and is a promising drug target. In silico methods reveal structural aspects of how it binds to its 11 natural cleavage sites, the design of novel peptide inhibitors, and insights into drug design.